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Primary infection with HIV leads to severe depletion of CD4 T cells. This effect 
is conveniently measured in the blood compartment, but is even more 
pronounced in the gastrointestinal tract, which may be the initial site of 
acquisition of HIV for some people(1). Persistent HIV gastrointestinal infection 
impairs local immune defences, leads to immune activation and disrupts the 
epithelial barrier. The epithelial dysfunction is not completely repaired by anti-
retroviral therapy (ART) that is effective enough to suppress HIV viral load in 
the blood to undetectable levels(1). At the microscopic level, disruption of tight 
junctions between adjacent columnar epithelial cells is seen as a component. 
The resulting loss of integrity of the epithelium allows translocation of bacteria 
into the bloodstream and this has been investigated as a potential contributor 
to the chronic systemic inflammation seen in HIV patients(2). 
 
These studies have now been supplemented by investigations to detect a viral 
pathogen in the gastrointestinal tract. Cytomegalovirus is found in the vast 
majority of HIV positive patients. Opportunistic disease, usually retinitis, 
caused by high viral loads of CMV are nowadays mostly prevented by ART, 
where this is available. However, there is extensive evidence that CMV 
infection, as opposed to overt disease, is not completely controlled by ART. It 
is known to infect endothelial, stromal and intestinal epithelial cells and may 
form ulcers to compromise the barrier function of the mucosa. It is known to 
disrupt tight junctions of retinal pigment epithelial cells, so might be able to do 
the same in epithelial cells of the gastrointestinal tract(3). It is possible 
therefore that it may contribute to the chronic gastrointestinal and systemic 
inflammation seen in HIV-positive patients. 
 
A recent publication combined immunohistochemistry with in situ hybridisation 
on primary intestinal cells differentiated to form monolayers of polarised 
cells(4). In this system, CMV decreased trans-epithelial electrical resistance, a 
method used to assess the integrity of an epithelial monolayer. Permeability 
was also changed when assessed by the ability of dextran labelled with a 
fluorescent dye to migrate across cells held in the compartments of a trans-
well apparatus. Only a few cells were CMV positive, raising the question of 
how an infection of limited scale could produce an effect across the whole 
epithelium. A contribution from interleukin-6 was identified, with the effect on 
epithelial integrity partially reduced by an antibody that blocked interleukin-6(4, 
5). The antiviral drugs ganciclovir or letermovir reduced the effect of CMV on 
the epithelium. Parallel studies on biopsies of rectosigmoid tissue provided 
evidence that similar effects take place in vivo(4). CMV proteins were readily 
detected in untreated HIV positive, CMV seropositive individuals. The quantity 
of cells expressing CMV proteins was reduced, but not abolished, in patients 
receiving ART. Tight junctions were disrupted and CMV DNA was present, 
thereby confirming productive CMV infection.  Rectosigmoid biopsies from 
HIV negative, CMV seropositive individuals did not contain CMV proteins in 
intestinal epithelial cells, although neighbouring cells stained positive, 
illustrating that the presence of HIV could alter the distribution of CMV. Finally, 
biopsies from an HIV positive case of CMV colitis showed damage to tight 
junctions which was no longer apparent in biopsies taken after a course of 
valganciclovir had been completed(4). 
 
Overall, this effect on gastrointestinal permeability should be classified along 
with the "indirect effects" of CMV which contrast with its “direct effects” of 
causing end-organ diseases such as retinitis. The indirect effects were 
originally described in allograft recipients and referred to CMV triggering graft 
rejections, contributing to the chronic inflammation that causes accelerated 
atherosclerosis or diverting immune responses to facilitate secondary 
bacterial or fungal infections(6). The concept of indirect effects was 
subsequently discussed in HIV-positive patients as a way of explaining 
complex phenomena, including accelerated progression to full-blown AIDS 
and an excess of deaths, where it was called a cofactor effect(7, 8). Cohort 
studies report a significant association between CMV and mortality with 
deaths reduced in those allocated to receive systemic ganciclovir rather than 
local therapy for retinitis(9-11). A randomised placebo-controlled trial in HIV 
positive individuals showed that valganciclovir decreased the abundance of 
the activated T cells that are the hallmark of chronic inflammation(12).  
 
It is clear from this new paper and others that there are multiple ways for this 
opportunistic virus to interact with different organ systems to produce disease 
without declaring its presence. This research is to be welcomed as a way of 
starting to tease out the contributions that this common virus makes to 
medically important conditions in patients with complex medical backgrounds. 
The results demonstrate clearly that CMV persistence in the gastrointestinal 
tract can, like bacterial infections, provoke chronic, systemic inflammation in 
HIV positive individuals. The challenge now is to determine if CMV represents 
just one of many examples of an infectious agent provoking chronic 
inflammation or whether CMV induced cytokine response is a central feature 
of pathogenesis that allows bacterial antigens to cross into the systemic 
circulation. In other words, would reduction of CMV gastrointestinal infection 
in a randomised placebo-controlled trial of an anti-CMV drug like 
valganciclovir in HIV positive individuals maintain normal intestinal barrier 
function? If so, would this reduce the adverse effects attributed both to CMV 
and to those caused by bacteria? 
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